Maury Raycroft
Stock Analyst at Jefferies
(0.64)
# 4,007
Out of 4,981 analysts
48
Total ratings
24.32%
Success rate
-14.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $328 → $384 | $465.89 | -17.58% | 2 | Jul 7, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.05 | +70.73% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $9.50 | +457.89% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $3.57 | +124.09% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.50 | +494.18% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $1.85 | +278.38% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.56 | +284.62% | 1 | Nov 18, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $6.53 | +190.96% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $4.07 | +268.55% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $37.16 | +4.95% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.74 | +709.17% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.86 | +1,136.56% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $10.26 | +1,801.51% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.91 | +39.06% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $23.77 | -74.76% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $29.72 | +152.36% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $7.69 | +43.04% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $12.54 | +115.31% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.83 | +173.22% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $54.91 | -12.58% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.92 | +303.59% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.39 | +1,848.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $56.26 | +205.72% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $3.25 | +1,346.15% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $3.93 | +5,759.87% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $11.42 | +267.78% | 3 | Nov 1, 2017 |
Alnylam Pharmaceuticals
Jul 7, 2025
Maintains: Buy
Price Target: $328 → $384
Current: $465.89
Upside: -17.58%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.05
Upside: +70.73%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $9.50
Upside: +457.89%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.57
Upside: +124.09%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.50
Upside: +494.18%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $1.85
Upside: +278.38%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.56
Upside: +284.62%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $6.53
Upside: +190.96%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $4.07
Upside: +268.55%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $37.16
Upside: +4.95%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.74
Upside: +709.17%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.86
Upside: +1,136.56%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $10.26
Upside: +1,801.51%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.91
Upside: +39.06%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $23.77
Upside: -74.76%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $29.72
Upside: +152.36%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $7.69
Upside: +43.04%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $12.54
Upside: +115.31%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.83
Upside: +173.22%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $54.91
Upside: -12.58%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $8.92
Upside: +303.59%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.39
Upside: +1,848.05%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $56.26
Upside: +205.72%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $3.25
Upside: +1,346.15%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $3.93
Upside: +5,759.87%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $11.42
Upside: +267.78%